MX2016016118A - Métodos de tratamiento de enfermedades y trastornos del neurodesarrollo. - Google Patents

Métodos de tratamiento de enfermedades y trastornos del neurodesarrollo.

Info

Publication number
MX2016016118A
MX2016016118A MX2016016118A MX2016016118A MX2016016118A MX 2016016118 A MX2016016118 A MX 2016016118A MX 2016016118 A MX2016016118 A MX 2016016118A MX 2016016118 A MX2016016118 A MX 2016016118A MX 2016016118 A MX2016016118 A MX 2016016118A
Authority
MX
Mexico
Prior art keywords
disorders
methods
prophylaxis
treatment
diseases
Prior art date
Application number
MX2016016118A
Other languages
English (en)
Inventor
CHEUNG Steve
Chin Boon Wah
Original Assignee
Univ Deakin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2014902173A external-priority patent/AU2014902173A0/en
Application filed by Univ Deakin filed Critical Univ Deakin
Publication of MX2016016118A publication Critical patent/MX2016016118A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/63—Arthropods
    • A61K35/64—Insects, e.g. bees, wasps or fleas
    • A61K35/644—Beeswax; Propolis; Royal jelly; Honey
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Insects & Arthropods (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Animal Husbandry (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere en general a métodos para el tratamiento y/o profilaxis de enfermedades neurológicas y trastornos que involucran la administración de trans 10-HDA. En particular, los métodos de la presente invención son útiles en el tratamiento y/o profilaxis de trastornos y condiciones del neurodesarrollo adquiridos o progresivos en mamíferos. Más particularmente, se enseñan aquí métodos para el tratamiento y/o la profilaxis de enfermedades y trastornos tales como trastornos del espectro autista.
MX2016016118A 2014-06-06 2015-06-05 Métodos de tratamiento de enfermedades y trastornos del neurodesarrollo. MX2016016118A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2014902173A AU2014902173A0 (en) 2014-06-06 Methods of treating neurodevelopmental diseases and disorders
PCT/AU2015/050310 WO2015184509A1 (en) 2014-06-06 2015-06-05 Methods of treating neurodevelopmental diseases and disorders

Publications (1)

Publication Number Publication Date
MX2016016118A true MX2016016118A (es) 2017-07-26

Family

ID=54765877

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016016118A MX2016016118A (es) 2014-06-06 2015-06-05 Métodos de tratamiento de enfermedades y trastornos del neurodesarrollo.

Country Status (11)

Country Link
US (3) US9925163B2 (es)
EP (1) EP3151824A4 (es)
JP (2) JP6598262B2 (es)
KR (1) KR102496390B1 (es)
CN (1) CN106659704B (es)
AU (2) AU2015271652B2 (es)
BR (1) BR112016028653A2 (es)
CA (1) CA2951288C (es)
MX (1) MX2016016118A (es)
NZ (1) NZ727412A (es)
WO (1) WO2015184509A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015271652B2 (en) * 2014-06-06 2021-05-27 Wah Chin Boon Methods of treating neurodevelopmental diseases and disorders
ES2952610T3 (es) * 2015-12-04 2023-11-02 Wah Chin Boon Métodos para tratar o aliviar trastornos mentales y síntomas asociados

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1025185A (en) 1911-03-23 1912-05-07 William J Gruss Regrinder.
JPH0967252A (ja) 1995-09-05 1997-03-11 Zenkoku Royal Jelly Kosei Torihiki Kiyougikai ローヤルゼリーに含まれるトランス−１０−ヒドロキシ−デセン酸を有効成分とするアンジオテンシン転換酵素阻害剤及びインスリン様作用剤
WO2007130581A2 (en) 2006-05-04 2007-11-15 Hardwicke Susan B Compositions and methods for psychiatric conditions and cognition enhancement
EP2457567B1 (en) 2007-09-19 2015-12-30 Nagoya Industrial Science Research Institute Agent having neurotrophic factor-like activity
KR101627001B1 (ko) 2008-06-17 2016-06-03 재팬 로얄 젤리 가부시키가이샤 인지 장해 개선제
EP2667715B1 (en) * 2011-01-27 2017-07-19 Neuren Pharmaceuticals Limited Treatment of autism spectrum disorders using glycyl-l-2-methylprolyl-l-glutamic acid
US10052319B2 (en) 2012-04-26 2018-08-21 Sumitomo Dainippon Pharma Co., Ltd. Medicament for treating mental and behavioural disorders
RU2602810C2 (ru) 2012-04-27 2016-11-20 Ниппон Дзоки Фармасьютикал Ко., Лтд. Производное транс-2-деценовой кислоты и содержащее его лекарственное средство
CN103816307B (zh) 2014-03-12 2016-09-14 张国显 神经生长再造丸及其制备方法
AU2015271652B2 (en) 2014-06-06 2021-05-27 Wah Chin Boon Methods of treating neurodevelopmental diseases and disorders
ES2952610T3 (es) 2015-12-04 2023-11-02 Wah Chin Boon Métodos para tratar o aliviar trastornos mentales y síntomas asociados

Also Published As

Publication number Publication date
WO2015184509A1 (en) 2015-12-10
KR20170026457A (ko) 2017-03-08
US9925163B2 (en) 2018-03-27
JP2019214623A (ja) 2019-12-19
US20190314315A1 (en) 2019-10-17
BR112016028653A2 (pt) 2018-07-10
EP3151824A1 (en) 2017-04-12
JP6598262B2 (ja) 2019-10-30
KR102496390B1 (ko) 2023-02-03
AU2015271652A1 (en) 2017-01-05
EP3151824A4 (en) 2017-12-20
AU2015271652B2 (en) 2021-05-27
CA2951288A1 (en) 2015-12-10
US10251856B2 (en) 2019-04-09
NZ727412A (en) 2023-07-28
JP2017517574A (ja) 2017-06-29
US20170087110A1 (en) 2017-03-30
JP6994613B2 (ja) 2022-01-14
US10933043B2 (en) 2021-03-02
CN106659704B (zh) 2020-03-10
CN106659704A (zh) 2017-05-10
AU2021221914A1 (en) 2021-09-23
CA2951288C (en) 2024-01-02
US20180214405A1 (en) 2018-08-02

Similar Documents

Publication Publication Date Title
GEP20247593B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
MX2017013562A (es) Reguladores de microbioma y usos relacionados de los mismos.
MX2018012655A (es) Compuestos y metodos para tratamiento de afecciones neurologicas y cardiovasculares.
MX2019003623A (es) Composiciones y metodos para el tratamiento de afecciones oftalmicas.
MX2017010150A (es) Bacterias probioticas recombinantes.
SG10201908028SA (en) Cyclopropylamines as lsd1 inhibitors
MX2015001250A (es) Composiciones y tratamiento para enfermedades y trastornos del ojo.
MX2018012902A (es) Composiciones y métodos para el tratamiento de trastornos de almacenamiento lisosomal y trastornos caracterizados por disfunción lisosomal.
PH12018500578A1 (en) Methods of treating inflammatory diseases
AU2018243836A1 (en) Gut-selective sequestering agents for the treatment and prevention of autism and related disorders
PH12019502363A1 (en) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds
MX2021007260A (es) Inhibidores de la vía de cinasa janus 1 (jak1) para el tratamiento de enfermedades gastrointestinales.
MX2018004220A (es) Tetrahidropiranilsulfonas sustituidas con pirazolilo.
MY195000A (en) Method for the treatment of neurological disease
MX2020009966A (es) Formas de dosificacion y usos terapeuticos de la l-4-cloro quinurenina.
PH12019500198A1 (en) Compounds and compositions and uses thereof
MX2018009662A (es) Metodo y composicion farmaceutica para tratamiento de neurodegeneracion.
MX2019004804A (es) Tratamiento para el prurigo nodula.
MX2018004217A (es) Tetrahidropiranilsulfonas sustituidas con pirazolilo.
SG10201805890QA (en) Compositions and methods for treatment of abnormal cell growth
MX2016016118A (es) Métodos de tratamiento de enfermedades y trastornos del neurodesarrollo.
PH12019502315A1 (en) Substituted n-arylethyl-2-aminoquinoline-4-carboxamides and use thereof
MX2016013451A (es) Heterociclilsulfonas arilo sustituidas.
PH12017501694A1 (en) Compositions for the treatment of fibrosis and fibrosis-related diseases
MX2019012153A (es) N-ariletil-2-arilquinolina -4-carboxamidas sustituidas y su uso.

Legal Events

Date Code Title Description
FG Grant or registration